China's genome editing startup EdiGene nets $62m in Series B+ round

China's genome editing startup EdiGene nets $62m in Series B+ round

Photo: Pixabay

22 April, 2021

EdiGENE ET-01 genome editing Loyal Valley Capital

Printed by Unregistered user on Sun, 07 Dec 2025 16:43:36 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

SoftBank to invest $900m in US gene sequencing firm Pacific Biosciences

COVID-19 test provider BGI Genomics raises $300m from Chinese govt agencies

Read more from Greater China

Alibaba to retire Ele.me brand amid instant-retail push

HongShan aims for $2.9b sale of Golden Goose to Permira by Christmas: report